达格列净应用合理性评价

    Evaluation of Application Rationality of Dapagliflozin

    • 摘要: 目的 建立达格列净临床应用合理性评价标准,采用属性层次模型法综合评价达格列净临床应用的合理性。方法 以达格列净说明书、中华医学会等发布的相关指南或专家共识为依据,制定达格列净药物利用评价标准。采用属性层次模型对2021年1—9月亳州市人民医院268例应用达格列净的归档病例进行分析评价。结果 达格列净应用主要不合理问题及占比为给药方式(91.0%)、用法用量(69.4%)、用药前评估(60.4%)、用药监护(53.7%)。达格列净应用的合理性评价结果:优秀90≤病例分值(medical record score,MRS)<10016例(6.0%),良好(70≤MRS<90)137例(51.1%),合格(60≤MRS<70)94例(35.1%),不合格(MRS<60)21例(7.8%)。结论 基于属性层次模型的药物利用评价操作简单,结果准确、可信,该方法将评价的多个指标整合,使评价结果更具有直观性,可在药物临床应用评价中推广。

       

      Abstract: OBJECTIVE To establish the rationality evaluation standard of clinical application of dapagliflozin and use the attribute hierarchical model to comprehensively evaluate the rationality of the clinical application of dapagliflozin. METHODS Based on the instructions of dapagliflozin, the relevant guidelines issued by the Chinese Medical Association, or the consensus of experts, the drug use evaluation standard of dapagliflozin was formulated. Attribute hierarchical model was used to analyze and evaluate 268 archived cases of dapagliflozin in Bozhou People’s Hospital from January to September 2021. RESULTS The main irrational problems and proportions of dapagliflozin were administration method(91.0%), usage and dosage(69.4%), pre-medication assessment(60.4%), and medication monitoring(53.7%). There were 16 excellent cases(6.0%) with 90≤medical record score(MRS)<100, 137 good cases(51.1%) with 70≤MRS<90, 94 qualified cases(35.1%) with 60≤MRS<70 and 21 disqualified cases(7.8%) with MRS<60. CONCLUSION The drug use evaluation based on the attribute hierarchical model has simple operation, accurate and credible results. The method integrates multiple evaluation indicators to make the evaluation results more intuitive and can be popularized in the evaluation of clinical applications of drugs.

       

    /

    返回文章
    返回